Click here to view the CareFirst BCBS Blue Cross Blue Shield Medical Policy Updates »…
BCBS Tennessee Medical Policy Updates – June 2021
Click here to view the Blue Cross Blue Shield BCBS Tennessee Medical Policy Updates »
June 2021 BCBS Tennessee Medical Policy Updates:
- AbobotulinumtoxinA
- Actigraphy
- Ado-Trastuzumab Emtansine
- Agalsidase
- Aldesleukin
- Alpha1PI
- Autonomic Nervous System Testing
- Avelumab
- Axicabtagene
- Azacitidine
- Belimumab
- Belimumab
- Bevacizumab for the Treatment of Neoplastic Disease
- Biofeedback and Neurofeedback
- Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Other Diseases Associated with High Bone Turnover
- Breast Cancer Gene Expression Assays
- Breast Implant Removal
- Burosumab
- Cabazitaxel
- Carfilzomib Kyprolis
- Casimersen (Amondys 45™)
- Cemiplimab
- Cetuximab
- Chromosomal Microarray Analysis for Evaluation of Pregnancy Loss
- Computerized 2-lead Resting Electrocardiogram Analysis for the Diagnosis of Coronary Artery Disease
- Conjunctival Challenge Test
- Coronary CTA
- Corticotropin
- Crizanlizumab-tmca
- Cytochrome p450 Genotyping
- Daratumumab
- Daunorubicin Cytarbine
- Denosumab
- Digital Breast Tomosynthesis (3D Mammogram)
- Emapalumab-lzsg
- Epoetin Alfa Dialysis
- Epoprostenol
- Eptinezumab
- Evinacumab-dgnb (Evkeeza™)
- Fam-trastuzumab Deruxtecan-nxki
- First Trimester Down
- Fosdenopterin (Nulibry™)
- Fractional Laser Treatment of Vulvovaginal Atrophy
- Gemcitabine
- Givosiran
- Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas
- Hemodialysis in the Home
- Idecabtagene
- Idursulfase
- IncobotulinumtoxinA
- IncobotulinumtoxinA
- Infliximab Biosimilar Products
- Ingestible pH and Pressure Capsule
- Intrastromal Corneal Ring Segments (ICRS) for Vision Correction
- Irinotecan Liposome
- Ixabepilone
- Laronidase
- Leukocyte Histamine Release Test (LHRT)
- Leuprolide
- Light Emitting Diode (LED) Therapy
- Lisocabtagene Maraleucel (Breyanzi®)
- Luspatercept
- Melphalan Flufenamide (Pepaxto®)
- Meth poly glycol epo beta dialysis
- Meth poly glycol epo beta non-dialysis
- Minimally Invasive Procedures for Weight Loss
- Mitomycin
- Necitumumab
- Nelarabine
- Neuromuscular Electrical Stimulation
- Nivolumab
- Nivolumab
- Octreotide
- Ofatumumab
- Omalizumab
- Omalizumab
- OnabotulinumtoxinA
- Osteochondral Allografting
- Paclitaxel
- Pembrolizumab
- Pemetrexed
- Pertuzumab
- PET Misc Applications
- Plugs for Anal Fistula Repair
- Pralatrexate
- Proteogenomic Testing for Individuals with Cancer
- Proteomics-based Testing for the Evaluation of Ovarian (Adnexal) Masses
- Pulmonary Arterial Hypertension Agents
- Ramucirumab
- Reduction Mammaplasty (Non-Cancerous)
- Rhinoplasty
- RimabotulinumtoxinB
- Rituximab
- Romiplostim
- Romosozumab-aqqg
- Sargramostim
- Siltuximab
- Sipuleucel-T
- Spinal Cord Stimulation / Peripheral Subcutaneous Field Stimulation for the Treatment of Pain
- Surface Electromyography (sEMG)
- Surgical Ventricular Restoration
- Tagraxofusp erzs
- Talimogene
- Temsirolimus
- Teprotumumab-trbw
- Testing Serum Vitamin D Levels
- Thyrotropin Alfa
- Transurethral Waterjet Ablation of the Prostate
- Triptorelin
- Vincristine Sulfate Liposome Injection
- Voretigene Neparvovec-rzyl
- Vulvectomy
- Whole Exome Genome
Additional June Updates:
- Ado-Trastuzumab Emtansine (Kadcyla®)
- Atezolizumab (Tecentriq®)
- Belantamab mafodotin-blmf
- Benralizumab
- Bevacizumab Products for the Treatment of Neoplastic Disease
- Blinatumomab
- Bortezomib
- Bortezomib
- Carfilzomib
- Cemiplimab-rwlc
- Darbepoetin Alfa for Dialysis (Aranesp®)
- Darbepoetin Alfa for Non-Dialysis (Aranesp®)
- Elosulfase Alfa
- Epoetin Alfa Products for Non-Dialysis
- Eribulin Mesylate
- Goserelin Acetate Implant (Zoladex®)
- Human Amniotic Membrane Grafts and Amniotic Fluid Injections
- Ibalizumab-uiyk (Trogarzo™)
- Idecabtagene Vicleucel (Abecma®)
- Ipilimumab (Yervoy®)
- Isatuximab-irfc (Sarclisa®)
- Levoleucovorin
- Lurbinectedin (Zepzelca™)
- Nivolumab (Opdivo®) (Intravenous)
- Noninvasive Techniques for Evaluation and Monitoring of Chronic Liver Diseases
- Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
- OnabotulinumtoxinA
- Panitumumab (Vectibix®)
- Pegfilgrastim Products (Neulasta®; Fulphila™; Udenyca®; Ziextenzo™; Nyvepria™)
- Pembrolizumab
- Pembrolizumab (Keytruda )
- Pemetrexed (Alimta®)
- Pemetrexed (Alimta®)
- Pertuzumab (Perjeta®)
- Rituximab Products (Rituxan®, Rituximab-abbs [Truxima®], Rituximab-arrx [Riabni™] and Rituximab-
- Sacituzumab Govitecan-hziy (Trodelvy®)
- Trastuzumab Products – Intravenous (Herceptin®, Ontruzant®, Herzuma ,®Ogivri ,®Trazimera™,
- Ziv-Aflibercept (Zaltrap®)
- Zoledronic Acid (Zometa®, Reclast®)
Click here to view the Blue Cross Blue Shield BCBS Tennessee Medical Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!
Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
